News for 'Sun Pharma Industries'

Sensex gains 106 points in highly volatile trade

Sensex gains 106 points in highly volatile trade

Rediff.com7 May 2025

From the 30-share Sensex firms, Tata Motors, Bajaj Finance, Eternal, Adani Ports, Tata Steel, Titan, Mahindra & Mahindra and Power Grid were among the gainers. Asian Paints, Sun Pharma, ITC, Nestle, Reliance Industries and HCL Tech were among the laggards.

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

Rediff.com20 Nov 2023

Pharmaceuticals major Mankind Pharma reported a 21 per cent year-on-year (Y-o-Y) increase in net profit, with revenue rising by 12 per cent Y-o-Y in the second quarter of the financial year 2024 (Q2FY24) in a regulatory filing lrecently.

Sun Pharma's Halol facility listed under USFDA import alert

Sun Pharma's Halol facility listed under USFDA import alert

Rediff.com8 Dec 2022

Sun Pharmaceutical Industries Ltd on Thursday said its Halol facility in Gujarat has been listed under import alert by the USFDA with products manufactured at the unit now are subject to refusal of admission in the US market. The development follows an inspection of the facility by the US Food and Drug Administration (USFDA) from April 26 to May 9, 2022. "We now wish to inform you that the company has received a communication from the USFDA stating that the facility has been listed under Import Alert," Sun Pharma said in a regulatory filing.

Indian pharma's Trump fears

Indian pharma's Trump fears

Rediff.com1 Feb 2017

Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.

Sensex, Nifty end n red on selling in IT, telecom stocks

Sensex, Nifty end n red on selling in IT, telecom stocks

Rediff.com12 Mar 2025

From the Sensex pack, Infosys, Tech Mahindra, Nestle India, Tata Consultancy Services, HCL Technologies, Asian Paints, Axis Bank, Zomato, Hindustan Unilever, and Bharti Airtel were among the laggards. On the other hand, IndusInd Bank, Tata Motors, Kotak Mahindra Bank, Bajaj Finance, HDFC Bank, ITC, Sun Pharma, Bajaj Finserv and UltraTech Cement were the gainers.

How India's pharma growth story fizzled out

How India's pharma growth story fizzled out

Rediff.com5 Jul 2017

Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.

Four IPOs worth Rs 6600 to hit D-Street next week

Four IPOs worth Rs 6600 to hit D-Street next week

Rediff.com25 May 2025

The initial public offering (IPO) lane will be busy next week, with four main-line companies, including Leela Palaces Hotels & Resorts operator Schloss Bangalore Ltd and Aegis Vopak Terminals tapping the primary market to raise over Rs 6,600 crore collectively.

Sensex goes into a tailspin, tanks 1,390 points

Sensex goes into a tailspin, tanks 1,390 points

Rediff.com1 Apr 2025

From the Sensex pack, HCL Tech, Bajaj Finserv, HDFC Bank, Bajaj Finance, Infosys, Titan, ICICI Bank, Sun Pharma, Reliance Industries, Larsen & Toubro, Tech Mahindra and NTPC were among the biggest laggards. Among gainers, IndusInd Bank jumped over 5 per cent while Zomato ended marginally higher.

Stock markets log biggest single-day rise; Sensex ends up 2975 points

Stock markets log biggest single-day rise; Sensex ends up 2975 points

Rediff.com12 May 2025

From the Sensex firms, Adani Ports, Eternal, Bajaj Finance, Axis Bank, Bajaj Finserv, Reliance Industries, Power Grid and NTPC were the major gainers. Sun Pharma, however, tanked over 5 per cent.

Customs to clear pharma raw materials from China

Customs to clear pharma raw materials from China

Rediff.com1 Jul 2020

Apart from them, consignments of 11 top importers, including LG, Samsung, Toyota, Honda, and Siemens, will also be allowed entry, relieving them of the 100 per cent inspection rule.

Indian pharma cos shifting R&D to SE Asian countries

Indian pharma cos shifting R&D to SE Asian countries

Rediff.com4 Jul 2013

South-east Asian countries are emerging as preferable destination for India's pharma companies to expand their business as they share similar patient population and disease profile and moreover, have a conducive environment for their operations like easy market approach without any regulatory uncertainty, the survey of Indian pharma firms highlighted.

'Trump Has No Enemies. He Has No Friends'

'Trump Has No Enemies. He Has No Friends'

Rediff.com17 May 2025

'In the Indian government there are no illusions about the United States reliability or the possibility of having any kind of preferential treatment from Washington when it comes to trade.'

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

Rediff.com3 Apr 2023

India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.

Markets join global selloff; Sensex sinks below 80k

Markets join global selloff; Sensex sinks below 80k

Rediff.com19 Dec 2024

Equity benchmark Sensex on Thursday plunged about 965 points to crash below the 80,000 level due to heavy selling in global equities after the US Federal Reserve signalled fewer rate cuts next year. Besides, deep losses in consumer durables, banking and IT stocks amid foreign fund outflows added to the gloom, analysts said.

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Rediff.com19 Jun 2023

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.

Sensex pares intra-day high to end up 598 points

Sensex pares intra-day high to end up 598 points

Rediff.com3 Dec 2024

From the 30-share Sensex pack, Adani Ports surged nearly 6 per cent. NTPC, Axis Bank, State Bank of India, Larsen & Toubro, UltraTech Cement, Tata Motors, HDFC Bank and Reliance Industries were the other big gainers. Bharti Airtel, ITC, Sun Pharma, Asian Paints and Kotak Mahindra Bank were the laggards.

GOOD News! No Drug Price Hike In 2024

GOOD News! No Drug Price Hike In 2024

Rediff.com6 Feb 2024

For the consumer, there would be practically no impact on prices of essential medicines this year.

PE fund Advent to buy Suven Pharma

PE fund Advent to buy Suven Pharma

Rediff.com26 Dec 2022

Global private equity investor Advent International on Monday said it is acquiring a significant stake in Suven Pharmaceuticals from its promoters, the Jasti family. The PE major said this will be followed with an open offer to acquire 26 per cent more in the listed contract development and manufacturing organisation from public shareholders, and also merge the company with investee company Cohance Lifesciences, as per an official statement. Media reports on a Monday morning pegged the acquisition at Rs 6,300 crore, and that Advent had pipped rival Blackstone for the acquisition.

Stock markets settle flat in muted trade

Stock markets settle flat in muted trade

Rediff.com26 Dec 2024

From the 30 blue-chip stocks, Titan, Asian Paints, Nestle, Tech Mahindra, Reliance Industries, Zomato, Larsen & Toubro and Bajaj Finserv were among the laggards. Adani Ports, Mahindra & Mahindra, Maruti, Sun Pharma, Bharti Airtel and Tata Motors were among the gainers.

Pushpa 2 stampede row: CM vows to back Telugu cinema

Pushpa 2 stampede row: CM vows to back Telugu cinema

Rediff.com26 Dec 2024

Declaring the Telangana government's support to the Telugu film industry, Chief Minister A Revanth Reddy on Thursday said the former would take steps to make Hyderabad a destination for international film shootings.

3 Indian pharma cos recall products in US market

3 Indian pharma cos recall products in US market

Rediff.com24 Apr 2022

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes. Similarly, Jubilant Cadista is recalling a drug which is used to treat different inflammatory conditions.

Sensex ends 322 points lower on selling in IT & Teck stocks

Sensex ends 322 points lower on selling in IT & Teck stocks

Rediff.com3 Apr 2025

From the Sensex pack, Tata Consultancy Services, HCL Technologies, Tech Mahindra, Infosys, Tata Motors, Bajaj Finance, Kotak Mahindra Bank, Mahindra & Mahindra, Bharti Airtel and Maruti Suzuki India, Tata Steel were the major laggards. PowerGrid, Sun Pharmaceuticals, UltraTech Cement, NTPC, Asian Paints, Nestle India, Titan, IndusInd Bank and Axis Bank were among the gainers.

India gets ready to face possible fallout of US tariffs

India gets ready to face possible fallout of US tariffs

Rediff.com1 Apr 2025

The commerce ministry is working on different scenarios to assess the possible fallout of reciprocal tariffs to be imposed by the US administration on April 2 on its key trading partners including India, sources said. US President Donald Trump has said that April 2 will be 'Liberation Day' as he plans to announce tariffs or import duties to bring down America's trade deficit, and promote the country's manufacturing.

US tariffs: India not in a hurry, to follow wait and watch approach

US tariffs: India not in a hurry, to follow wait and watch approach

Rediff.com3 Apr 2025

The official said there are both challenges and opportunities for India as many of its competitor countries in exports, such as China Vietnam, Bangladesh, Cambodia and Thailand, face higher duties.

Torrent Group acquires 67% stake in Gujarat Titans

Torrent Group acquires 67% stake in Gujarat Titans

Rediff.com17 Mar 2025

Ahmedabad-based Torrent Group has completed the acquisition of a majority 67 percent stake in Indian Premier League (IPL) franchise Gujarat Titans.

Pharma sector to top Rs 60,000 cr by '08

Pharma sector to top Rs 60,000 cr by '08

Rediff.com20 Sep 2005

Industry body Assocham on Tuesday said the Indian pharma industry would grow at 11 per cent to touch Rs 60,000 crore (Rs 600 billion) in 2007-08 from Rs 39,000 crore (Rs 390 billion) in 2003-04, when drugs worth $65 billion would go off patent.

India Inc feels the heat of West Asia conflict

India Inc feels the heat of West Asia conflict

Rediff.com29 Apr 2024

Closely watched by the world for any escalation, the Iran-Israel conflict is already showing early signs of stress for India Inc - longer deliveries, doubling freight rates, extended working capital cycles, and higher costs. For those yet to feel the heat, there is growing apprehension and nervousness over future developments, observed industry executives.

Sensex, Nifty tank nearly 1% on selloff in banking, IT stocks

Sensex, Nifty tank nearly 1% on selloff in banking, IT stocks

Rediff.com3 Jan 2025

From the Sensex pack, Zomato, HDFC Bank, Tech Mahindra, Adani Ports, Tata Consultancy Services, ICICI Bank, Sun Pharma, Larsen & Toubro, HCL Tech and ITC were the major laggards. On the other hand, Tata Motors, Nestle, Titan, Hindustan Unilever and Reliance Industries were among the gainers.

Siemens stock drops rapidly as management flags growth challenges ahead

Siemens stock drops rapidly as management flags growth challenges ahead

Rediff.com31 Dec 2024

Siemens's share price has lost ground in the past few sessions following weak management commentary. The management indicated challenges to the growth outlook due to stagnant private capex and concerns over semiconductor shortages for digital industries. Government infra-spending may regain momentum from January 2025.

Medtech MNCs bet big on localisation

Medtech MNCs bet big on localisation

Rediff.com12 May 2025

Several multinational medical device makers are focusing on deepening their presence in India by expanding their local manufacturing footprint and research capabilities, a move that can catapult India into a strategic hub for the medical technology (medtech) industry. Among those increasing their reach in the country are Siemens Healthineers and Philips, signalling a broader shift from India being only a sales destination to becoming a global production and innovation base.

GDP growth projection spooks markets; Sensex down 51 points

GDP growth projection spooks markets; Sensex down 51 points

Rediff.com8 Jan 2025

From the 30-share blue-chip pack, Adani Ports, UltraTech Cement, Larsen & Toubro, Sun Pharma, HDFC Bank, ICICI Bank, NTPC and State Bank of India were the major laggards. Tata Consultancy Services, Reliance Industries, ITC, Asian Paints, HCL Tech and Maruti were among the gainers.

Trump's Tariffs: India Should Be Worried

Trump's Tariffs: India Should Be Worried

Rediff.com4 Apr 2025

While growth in India is largely domestic and hence the overall GDP effect may not be more than 0.15-0.2%, but overall trade will be impacted due to every country going back to the drawing board, points out Madan Sabnavis.

Modi raises anti-India activities in NZ with visiting PM

Modi raises anti-India activities in NZ with visiting PM

Rediff.com17 Mar 2025

India and New Zealand have signed a pact to institutionalize their defence ties and vowed to boost cooperation in the Indo-Pacific. Prime Minister Narendra Modi raised concerns about anti-India activities by some illegal elements in New Zealand with his Kiwi counterpart Christopher Luxon. The two sides also signed six agreements to enhance cooperation in areas including education, sports, agriculture, and climate change. They also agreed to prepare a roadmap for cooperation in the defence industry sector and explore early implementation of cooperation in the digital payments sector.

Banking, FMCG, pharma shares drag Sensex down 366 points

Banking, FMCG, pharma shares drag Sensex down 366 points

Rediff.com11 Aug 2023

From the Sensex pack, IndusInd Bank, NTPC, Asian Paints, Hindustan Unilever, JSW Steel, Tech Mahindra, Bajaj Finance, Infosys, Wipro, ICICI Bank, Bajaj Finserv, HDFC Bank and Tata Motors were among the major laggards. HCL Technologies, Power Grid, Titan, Reliance Industries, UltraTech Cement, Tata Steel, State Bank of India and Mahindra & Mahindra were the gainers.

House panel for 'blanket ban' on FDI in pharma

House panel for 'blanket ban' on FDI in pharma

Rediff.com14 Aug 2013

The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.

Trump Tariffs: Time To Rejig Portolio

Trump Tariffs: Time To Rejig Portolio

Rediff.com4 Apr 2025

Investors should tilt their portfolios towards domestic-facing defensive sectors, which should help provide stability and shield them from geopolitical and tariff risks.

Help our industry, like we help yours: India tells China

Help our industry, like we help yours: India tells China

Rediff.com29 Sep 2010

After creating a 'level-playing field' for Chinese telecom companies doing business in India, New Delhi has asked Beijing to reciprocate by creating opportunities for its IT and pharma industry.

Bengaluru leads as top job hub with 9.3% salary growth: Report

Bengaluru leads as top job hub with 9.3% salary growth: Report

Rediff.com24 Oct 2024

Bengaluru dominated as the country's top city for job opportunities and salary growth as it has registered a 9.3 per cent year-on-year increase, closely followed by Chennai and Delhi, a report said on Thursday. This growth underlines Bengaluru's reputation as a technology and business hub as the average monthly unified salary in the city stood at Rs 29,500, making it the highest-paying city in the country, according to TeamLease Services Jobs and Salaries Primer report for FY24. The report is based on an analysis of unified salaries across temporary and permanent hiring markets.

Equity markets likely to trade in positive territory on Friday

Equity markets likely to trade in positive territory on Friday

Rediff.com10 Apr 2025

Domestic benchmark equity indices may see a positive trading sentiment on Friday thanks to a spectacular rally in world markets after the US President Donald Trump announced to put tariff hikes on hold for 90 days, excluding China from the reprieve. Indian stock markets were closed on Thursday for Shri Mahavir Jayanti. Trump has declared a three-month pause on reciprocal tariffs on non-retaliating countries marking a rather unexpected U-turn after record high levies he imposed led to global stock market meltdown.